Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation

ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacy and pharmacology 1999-02, Vol.51 (2), p.135-139
Hauptverfasser: HOMER, KERRY L., FIORE, STEVEN A., WANSTALL, JANET C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 139
container_issue 2
container_start_page 135
container_title Journal of pharmacy and pharmacology
container_volume 51
creator HOMER, KERRY L.
FIORE, STEVEN A.
WANSTALL, JANET C.
description ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO. On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase. NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.
doi_str_mv 10.1211/0022357991772240
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69709870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69709870</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3620-416466239eae777c8d186a3f5a915cb80a710c0c61aa2fa9e5236299e66295433</originalsourceid><addsrcrecordid>eNpdkU1vEzEQhlcIREPhzgn5gBCVYvDHrh1zq9qSpJQkBFAPVWVNNrOKYWOn612R8LP4hewqASpOI8087ztfSfKcszdccP6WMSFkpo3hWguRsgdJT7BUUM2zwcOk15VpW5dHyZMYvzHGtFLqcXLEmeBact5Lfo39yi1c7YInix3hI3rD-6Kf3k63sHTwM5ThJu1LCrd3jfNhC6XzlNPgkbyenn86IaEgc4yb4CNGUgcycXXlcjLduiXSZfChisR5MoeazJpyHTxUO3Ja1Vjt3pGxL8oGfY6dTb1C8hHzFXgX113ivhUZoscKujmfJo8KKCM-O8Tj5Ov7iy9nI3o1HY7PTq-ok0owmnKVKiWkQUCtdT5Y8oECWWRgeJYvBgw0ZznLFQcQBRjMRKszBluRyVIpj5NXe99NFe4ajLVdu5hjWYLH0ESrjGZmoFkLvjiAzWKNS7up3Lrd0v65cgu8PAAQcyiLCnzu4j9OM21E1mLZHvvhStzds7Hds-3_z7aXs9EsNV1_ute5WOP2rw6q71ZpqTN7PRnaD9d6fqnOJ_az_A3i-ajU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69709870</pqid></control><display><type>article</type><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</creator><creatorcontrib>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</creatorcontrib><description>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO. On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase. NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</description><identifier>ISSN: 0022-3573</identifier><identifier>EISSN: 2042-7158</identifier><identifier>DOI: 10.1211/0022357991772240</identifier><identifier>PMID: 10217311</identifier><identifier>CODEN: JPPMAB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiovascular system ; Dose-Response Relationship, Drug ; Enzyme Inhibitors - pharmacology ; Guanylate Cyclase - antagonists &amp; inhibitors ; Hydrazines - pharmacology ; In Vitro Techniques ; Male ; Medical sciences ; Molsidomine - analogs &amp; derivatives ; Molsidomine - pharmacology ; Nitric Oxide - biosynthesis ; Nitric Oxide Donors - pharmacology ; Nitro Compounds - pharmacology ; Nitrogen Oxides ; Oxadiazoles - pharmacology ; Pharmacology. Drug treatments ; Pulmonary Artery - drug effects ; Pulmonary Artery - physiology ; Quinoxalines - pharmacology ; Rats ; Rats, Wistar ; Spermine - analogs &amp; derivatives ; Spermine - pharmacology ; Vasodilation - drug effects</subject><ispartof>Journal of pharmacy and pharmacology, 1999-02, Vol.51 (2), p.135-139</ispartof><rights>1999 Royal Pharmaceutical Society of Great Britain</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1211%2F0022357991772240$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1211%2F0022357991772240$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1707925$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10217311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOMER, KERRY L.</creatorcontrib><creatorcontrib>FIORE, STEVEN A.</creatorcontrib><creatorcontrib>WANSTALL, JANET C.</creatorcontrib><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><title>Journal of pharmacy and pharmacology</title><addtitle>J Pharm Pharmacol</addtitle><description>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO. On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase. NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</description><subject>Animals</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Guanylate Cyclase - antagonists &amp; inhibitors</subject><subject>Hydrazines - pharmacology</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molsidomine - analogs &amp; derivatives</subject><subject>Molsidomine - pharmacology</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Nitro Compounds - pharmacology</subject><subject>Nitrogen Oxides</subject><subject>Oxadiazoles - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary Artery - drug effects</subject><subject>Pulmonary Artery - physiology</subject><subject>Quinoxalines - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Spermine - analogs &amp; derivatives</subject><subject>Spermine - pharmacology</subject><subject>Vasodilation - drug effects</subject><issn>0022-3573</issn><issn>2042-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1vEzEQhlcIREPhzgn5gBCVYvDHrh1zq9qSpJQkBFAPVWVNNrOKYWOn612R8LP4hewqASpOI8087ztfSfKcszdccP6WMSFkpo3hWguRsgdJT7BUUM2zwcOk15VpW5dHyZMYvzHGtFLqcXLEmeBact5Lfo39yi1c7YInix3hI3rD-6Kf3k63sHTwM5ThJu1LCrd3jfNhC6XzlNPgkbyenn86IaEgc4yb4CNGUgcycXXlcjLduiXSZfChisR5MoeazJpyHTxUO3Ja1Vjt3pGxL8oGfY6dTb1C8hHzFXgX113ivhUZoscKujmfJo8KKCM-O8Tj5Ov7iy9nI3o1HY7PTq-ok0owmnKVKiWkQUCtdT5Y8oECWWRgeJYvBgw0ZznLFQcQBRjMRKszBluRyVIpj5NXe99NFe4ajLVdu5hjWYLH0ESrjGZmoFkLvjiAzWKNS7up3Lrd0v65cgu8PAAQcyiLCnzu4j9OM21E1mLZHvvhStzds7Hds-3_z7aXs9EsNV1_ute5WOP2rw6q71ZpqTN7PRnaD9d6fqnOJ_az_A3i-ajU</recordid><startdate>199902</startdate><enddate>199902</enddate><creator>HOMER, KERRY L.</creator><creator>FIORE, STEVEN A.</creator><creator>WANSTALL, JANET C.</creator><general>Blackwell Publishing Ltd</general><general>Pharmaceutical Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199902</creationdate><title>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</title><author>HOMER, KERRY L. ; FIORE, STEVEN A. ; WANSTALL, JANET C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3620-416466239eae777c8d186a3f5a915cb80a710c0c61aa2fa9e5236299e66295433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Guanylate Cyclase - antagonists &amp; inhibitors</topic><topic>Hydrazines - pharmacology</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molsidomine - analogs &amp; derivatives</topic><topic>Molsidomine - pharmacology</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Nitro Compounds - pharmacology</topic><topic>Nitrogen Oxides</topic><topic>Oxadiazoles - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary Artery - drug effects</topic><topic>Pulmonary Artery - physiology</topic><topic>Quinoxalines - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Spermine - analogs &amp; derivatives</topic><topic>Spermine - pharmacology</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOMER, KERRY L.</creatorcontrib><creatorcontrib>FIORE, STEVEN A.</creatorcontrib><creatorcontrib>WANSTALL, JANET C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOMER, KERRY L.</au><au>FIORE, STEVEN A.</au><au>WANSTALL, JANET C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation</atitle><jtitle>Journal of pharmacy and pharmacology</jtitle><addtitle>J Pharm Pharmacol</addtitle><date>1999-02</date><risdate>1999</risdate><volume>51</volume><issue>2</issue><spage>135</spage><epage>139</epage><pages>135-139</pages><issn>0022-3573</issn><eissn>2042-7158</eissn><coden>JPPMAB</coden><abstract>ODQ, (1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one, an inhibitor of soluble guanylate cyclase) inhibits vasorelaxant responses to nitric oxide (NO)‐donor drugs, but the extent of the inhibition varies depending on the NO donor studied. The purpose of this study was to test the hypothesis that these variations in the effects of ODQ reflect differences in the mechanisms whereby each NO donor generates NO. On pulmonary artery preparations pre‐contracted submaximally with phenylephrine, ODQ (3 μM) almost abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and nitroprusside; each of these drugs requires activation in the tissue (by enzymes or reducing agents) to generate NO. In contrast, ODQ (3 μM) caused a parallel shift in the concentration‐relaxation curves to linsidomine (SIN‐1), FK409, MAHMA NONOate and spermine NONOate (1.63 to 2.54 log units) with no depression in maximum response; each of these NO donors generates NO in the physiological bathing solution without requiring tissue activation. For the four drugs in this group, the effects of 10 μM ODQ were not significantly greater than the effects of 3 μM ODQ; thus there was an ODQ‐resistant component to the response suggesting that part of the response involved a mechanism that was independent of soluble guanylate cyclase. NO donors that require tissue activation probably generate NO within the smooth‐muscle cell, whereas those that do not require tissue activation generate NO outside the cell. Hence it is concluded that the site of NO generation (intra‐ or extracellular) might determine whether or not there is an ODQ‐resistant component in the relaxation response.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10217311</pmid><doi>10.1211/0022357991772240</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3573
ispartof Journal of pharmacy and pharmacology, 1999-02, Vol.51 (2), p.135-139
issn 0022-3573
2042-7158
language eng
recordid cdi_proquest_miscellaneous_69709870
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Animals
Antianginal agents. Coronary vasodilator agents
Biological and medical sciences
Cardiovascular system
Dose-Response Relationship, Drug
Enzyme Inhibitors - pharmacology
Guanylate Cyclase - antagonists & inhibitors
Hydrazines - pharmacology
In Vitro Techniques
Male
Medical sciences
Molsidomine - analogs & derivatives
Molsidomine - pharmacology
Nitric Oxide - biosynthesis
Nitric Oxide Donors - pharmacology
Nitro Compounds - pharmacology
Nitrogen Oxides
Oxadiazoles - pharmacology
Pharmacology. Drug treatments
Pulmonary Artery - drug effects
Pulmonary Artery - physiology
Quinoxalines - pharmacology
Rats
Rats, Wistar
Spermine - analogs & derivatives
Spermine - pharmacology
Vasodilation - drug effects
title Inhibition by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of Responses to Nitric Oxide-donors in Rat Pulmonary Artery: Influence of the Mechanism of Nitric Oxide Generation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20by%201H-%5B1,2,4%5DOxadiazolo%5B4,3-a%5Dquinoxalin-1-one%20(ODQ)%20of%20Responses%20to%20Nitric%20Oxide-donors%20in%20Rat%20Pulmonary%20Artery:%20Influence%20of%20the%20Mechanism%20of%20Nitric%20Oxide%20Generation&rft.jtitle=Journal%20of%20pharmacy%20and%20pharmacology&rft.au=HOMER,%20KERRY%20L.&rft.date=1999-02&rft.volume=51&rft.issue=2&rft.spage=135&rft.epage=139&rft.pages=135-139&rft.issn=0022-3573&rft.eissn=2042-7158&rft.coden=JPPMAB&rft_id=info:doi/10.1211/0022357991772240&rft_dat=%3Cproquest_pubme%3E69709870%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69709870&rft_id=info:pmid/10217311&rfr_iscdi=true